News Agency
The Times

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

  • Written by PR Newswire
  • ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing.
  • ASC30 oral tablet was generally safe and well tolerated. All adverse events (AEs) were mild (grade 1) or...

Read more: Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small...

How Australian Businesses Can Prepare Their Websites for AI-Powered Search Results

Search is changing rapidly. While traditional search engines remain a major source of website traffic, customers are increasingly using AI-powered platforms to discover information, compare businesses and make purchasing decisions. For Australian businesses, this shift creates a new challenge: ensuring... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion